featured
Efficacy of In-Class Interleukin-23 Inhibitor Switching in Psoriasis Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of In-Class Interleukin-23 Inhibitor Switching: Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Treatment
Br J Dermatol 2020 Sep 30;[EPub Ahead of Print], R Reddy, S Pannu, K Fiumara, J Kahn, D RosmarinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.